Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The safety of gliptins : updated data in 2018
André Scheen
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 4, pp. 387-405
Closed Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 351
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 332
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 292
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 642-653
Closed Access | Times Cited: 270
An update on the safety of SGLT2 inhibitors
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Jens J. Holst
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 104
Multi-Target Approaches in Metabolic Syndrome
Felix F. Lillich, John D. Imig, Ewgenij Proschak
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 93
Diabetes pharmacotherapy and effects on the musculoskeletal system
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu, et al.
Diabetes/Metabolism Research and Reviews (2018) Vol. 35, Iss. 2
Open Access | Times Cited: 86
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Ruili Yin, Yongsong Xu, Xin Wang, et al.
Molecules (2022) Vol. 27, Iss. 10, pp. 3055-3055
Open Access | Times Cited: 50
Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 331-331
Open Access | Times Cited: 40
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Lixin Guo, Xinhua Xiao
Aging Medicine (2024) Vol. 7, Iss. 1, pp. 5-51
Open Access | Times Cited: 9
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Giorgio Sesti, Angelo Avogaro, S Belcastro, et al.
Acta Diabetologica (2019) Vol. 56, Iss. 6, pp. 605-617
Closed Access | Times Cited: 63
New-Onset Diabetes after Kidney Transplantation
Claudio Ponticelli, Evaldo Favi, Mariano Ferraresso
Medicina (2021) Vol. 57, Iss. 3, pp. 250-250
Open Access | Times Cited: 50
Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Current Molecular Pharmacology (2021) Vol. 15, Iss. 4, pp. 683-692
Closed Access | Times Cited: 45
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?
Rossana Roncato, Jacopo Angelini, Arianna Pani, et al.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2022) Vol. 1867, Iss. 6, pp. 159140-159140
Open Access | Times Cited: 31
A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
Srishti Chhabria, Shivangi Mathur, Sebastian Vadakan, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 30
Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
Xiaowei Zhang, Zhiwei Zhang, Yajuan Yang, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 55
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
André Scheen
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101213-101213
Open Access | Times Cited: 42
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 2, pp. 101325-101325
Closed Access | Times Cited: 26
Engineered probiotics Clostridium butyricum‐pMTL007‐GLP‐1 improves blood pressure via producing GLP‐1 and modulating gut microbiota in spontaneous hypertension rat models
X Wang, Wen‐jie Chen, Rui Jin, et al.
Microbial Biotechnology (2022) Vol. 16, Iss. 4, pp. 799-812
Open Access | Times Cited: 23
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design
Ravi Kant, Ramesh Babu Bodla, Garima Kapoor, et al.
Bioorganic Chemistry (2019) Vol. 91, pp. 103111-103111
Closed Access | Times Cited: 39
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 3, pp. 186-196
Closed Access | Times Cited: 38
Discovery of Novel 1,3,5-triazine Derivatives As an Antidiabetic Agent in Wistar Rats Via Inhibition of DPP-4
Akanksha Gupta, Hans Raj Bhat, Udaya Pratap Singh
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 829-852
Closed Access | Times Cited: 12
Modulation of dipeptidyl peptidase IV by Rooibos tea metabolites towards type 2 diabetes care: Evidence from molecular dynamics simulation and density functional theory
Lukman HY, Aribisala JO, Ayesha Akoonjee, et al.
Scientific African (2024) Vol. 24, pp. e02173-e02173
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top